Related Experiment Video
Updated: Jun 26, 2026

Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling
Published on: September 20, 2016
Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC)
Ze-jun Lu1, Qi-fang Song, Sa-sa Jiang
1Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 37 Guoxue Xiang Street, Chengdu 610041, Sichuan, PR China. luzejun.01@163.com
Background:
Antibody-based immunotherapy has achieved some success for cancer. But the main problem is that only a few tumor-associated antigens or therapeutic targets have been known to us so far. It is essential to identify more immunogenic antigens (especially cellular membrane markers) for tumor diagnosis and therapy.
Methods:
The membrane proteins of lung adenocarcinoma cell line A549 were used to immunize the BALB/c mice. A monoclonal antibody 4E7 (McAb4E7) was produced with hybridoma technique. MTT cell proliferation assay was carried out to evaluate the inhibitory effect of McAb4E7 on A549 cells. Flow cytometric assay, immunohistochemistry, western blot and proteomic technologies based on 2-DE and mass spectrometry were employed to detect and identify the corresponding antigen of McAb4E7.
Results:
The monoclonal antibody 4E7 (McAb4E7) specific against A549 cells was produced, which exhibited inhibitory effect on the proliferation of A549 cells. By the proteomic technologies, we identified that ATP synthase beta subunit (ATPB) was the corresponding antigen of McAb4E7. Then, flow cytometric analysis demonstrated the localization of the targeting antigen of McAb4E7 was on the A549 cells surface. Furthermore, immunohistochemistry showed that the antigen of McAb4E7 mainly aberrantly expressed in tumor cellular membrane in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC). The rate of ectopic expressed ATPB in the cellular membrane in lung adenocarcinoma, squamous carcinoma and their adjacent nontumourous lung tissues was 71.88%, 66.67% and 25.81% respectively.
Conclusion:
In the present study, we identified that the ectopic ATPB in tumor cellular membrane was the non-small cell lung cancer (NSCLC) associated antigen. ATPB may be a potential biomarker and therapeutic target for the immunotherapy of NSCLC.
Insights
Researchers identified ATP synthase beta subunit (ATPB) as a novel lung cancer biomarker. This ectopically expressed protein on tumor cell membranes shows promise for non-small cell lung cancer (NSCLC) diagnosis and immunotherapy.
Area of Science:
- Oncology
- Immunotherapy
- Biomarker Discovery
Background:
- Antibody-based cancer immunotherapy shows promise but is limited by the scarcity of known tumor antigens.
- Identifying novel, immunogenic antigens, particularly cell membrane markers, is crucial for advancing cancer diagnosis and therapy.
Purpose of the Study:
- To identify novel tumor-associated antigens for non-small cell lung cancer (NSCLC) immunotherapy.
- To develop a monoclonal antibody targeting a specific lung cancer antigen.
- To evaluate the potential of the identified antigen as a diagnostic biomarker and therapeutic target.
Main Methods:
- Immunization of mice with lung adenocarcinoma cell membrane proteins to generate monoclonal antibody 4E7 (McAb4E7).
- Utilized hybridoma technique, MTT assay, flow cytometry, immunohistochemistry, Western blot, and proteomic technologies (2-DE, mass spectrometry) for antigen identification and validation.
- Assessed McAb4E7's inhibitory effect on A549 cell proliferation.
Main Results:
- Successfully produced McAb4E7 with inhibitory effects on A549 cell proliferation.
- Identified ATP synthase beta subunit (ATPB) as the target antigen for McAb4E7 using proteomic analysis.
- Confirmed ATPB's surface localization on A549 cells via flow cytometry.
- Immunohistochemistry revealed aberrant ATPB expression in tumor cell membranes of NSCLC (adenocarcinoma and squamous carcinoma) but not in small cell lung cancer (SCLC), with high ectopic expression rates (71.88% and 66.67% respectively).
Conclusions:
- Ectopic ATPB in the tumor cell membrane is identified as a non-small cell lung cancer (NSCLC)-associated antigen.
- ATPB demonstrates potential as a biomarker for NSCLC diagnosis and a therapeutic target for NSCLC immunotherapy.
More Related Videos
Related Concept Videos
ATP Synthase: Mechanism
The ADP/ATP Carrier Protein
ATP Synthase: Structure
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Selectins

